Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. November 2019 08:00 ET | Quelle: resTORbio, Inc.

resTORbio to Present at Upcoming Investor Conferences

BOSTON, Nov. 26, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
15. November 2019 07:00 ET | Quelle: resTORbio, Inc.

resTORbio Announces That the Phase 3 PROTECTOR 1 Trial of RTB101 in Clinically Symptomatic Respiratory Illness Did Not Meet the Primary Endpoint

-- Company stops further development of clinically symptomatic respiratory illness indication but continues development of RTB101 in other aging-related diseases, including Parkinson’s disease -- --...
05. November 2019 07:00 ET | Quelle: resTORbio, Inc.

resTORbio Reports Third Quarter 2019 Financial Results and Corporate Update

Top-line data from PROTECTOR 1 study expected by early first quarter of 2020 RTB101 Phase 2b data demonstrating upregulation of innate antiviral immunity presented at IDWeek™ 2019 BOSTON, Nov. 05,...
02. Oktober 2019 06:00 ET | Quelle: resTORbio, Inc.

resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019

BOSTON, Oct. 02, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
25. September 2019 08:00 ET | Quelle: resTORbio, Inc.

resTORbio to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

BOSTON, Sept. 25, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
23. September 2019 08:09 ET | Quelle: resTORbio, Inc.

resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019

BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
14. August 2019 07:31 ET | Quelle: resTORbio, Inc.

resTORbio Reports Second Quarter 2019 Financial Results and Corporate Update

– Quarter highlighted by initiation and early completion of enrollment of Phase 3 PROTECTOR 1 trial; topline data expected by early first quarter of 2020 – BOSTON, Aug. 14, 2019 (GLOBE...
07. August 2019 09:01 ET | Quelle: resTORbio, Inc.

resTORbio to Present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019

BOSTON, Aug. 07, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
23. Juli 2019 07:01 ET | Quelle: resTORbio, Inc.

resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness

– Company plans to announce topline data from PROTECTOR 1 by early first quarter of 2020 – – PROTECTOR 2 is planned to start in the fourth quarter of 2019, with topline data expected in mid-2020 – ...
20. Mai 2019 08:00 ET | Quelle: resTORbio, Inc.

resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections in Patients 65 Years of Age and Older with Asthma

RTB101 10 mg once daily was observed to reduce the rate of laboratory-confirmed Respiratory Tract Infections (RTIs) by 78.7% (p=0.001) and the rate of all RTIs (with or without laboratory...

Vorherige Seite